| SPYRE THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US00773J2024 / A3D4LY |
| 3920 (Frankfurt) / SYRE (NASDAQ) |
| FRA:3920, ETR:3920, 3920:GR, NASDAQ:SYRE |
| - |
| https://spyre.com/ |
|
Spyre Therapeutics Inc. operates as a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. Its primary function is to research and bring to market novel medicines that target the underlying ca..
>Volltext.. |
| 3327.18 Mio. EUR |
| 2815.95 Mio. EUR |
| - |
| -190.21 Mio. EUR |
| -117.66 Mio. EUR |
| -1.8 EUR |
| - |
| 74.26 Mio. EUR |
| -146.77 Mio. EUR |
| 12.89 |
| - |
| 20.48% |
| - |
| - |
| - |
| SPYRE THERAPEUTICS, SPYRE THERAPEUTIC |
| 05.04.26 |
|